DSP cardiomyopathy is a distinct clinical entity characterized by left ventricular fibrosis and ventricular arrhythmias, necessitating a genotype-specific approach to diagnosis and risk stratification.
Answers are grounded in this paper and cite their sources.
Supports DSP-specific evaluation in cardiomyopathy; leaves open prospective validation of risk stratification.
DSP cardiomyopathy is a distinct form of arrhythmogenic cardiomyopathy characterized by episodic myocardial injury, left ventricular fibrosis that precedes systolic dysfunction, and a high incidence of ventricular arrhythmias. A genotype-specific approach for diagnosis and risk stratification should be used.
No takes yet. Share an insight, caveat, or question.
Smith et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: